Merck says court ruled in its favor over patent-infringement suit

Breaking News

Drugmaker Merck & Co. MRK on Tuesday said that a U.S. district court had validated U.S. patent protection for its neuromuscular drug Bridion through “at least January 2026.” The announcement followed what the company said was a favorable ruling from the U.S. District Court for the District of New Jersey over a patent-infringement lawsuit related to the drug, which according to the FDA is administered to reverse the effects of other drugs used to paralyze a patient’s vocal cords and allow breathing-tube insertion for surgery. Merck said the court “found that Merck correctly calculated the Patent Term Extension period for…

Original Post

Articles You May Like

Former U.S. ambassador spied for Cuba for decades: DOJ
Notable Monday Option Activity: DPZ, IIPR, KSS
Jada Pinkett Smith on finding self-worth beyond celebrity, and 50
Mortgage refinance demand jumps as rates fall
How to start earning from stock market? | Share market basics for beginners | Stock market Class |

Leave a Reply

Your email address will not be published. Required fields are marked *